James Edgemond Sells 21,000 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) CFO James Edgemond sold 21,000 shares of United Therapeutics stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $479.99, for a total value of $10,079,790.00. Following the completion of the transaction, the chief financial officer owned 8,142 shares in the company, valued at approximately $3,908,078.58. This represents a 72.06% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

James Edgemond also recently made the following trade(s):

• On Monday, November 24th, James Edgemond sold 21,000 shares of United Therapeutics stock. The stock was sold at an average price of $473.64, for a total transaction of $9,946,440.00.
• On Monday, November 17th, James Edgemond sold 21,000 shares of United Therapeutics stock. The shares were sold at an average price of $470.36, for a total transaction of $9,877,560.00.
• On Monday, November 10th, James Edgemond sold 21,000 shares of United Therapeutics stock. The shares were sold at an average price of $452.07, for a total transaction of $9,493,470.00.
• On Tuesday, November 4th, James Edgemond sold 21,000 shares of United Therapeutics stock. The shares were sold at an average price of $436.09, for a total transaction of $9,157,890.00.

United Therapeutics Trading Down 1.2%

United Therapeutics stock traded down $5.81 during mid-day trading on Tuesday, reaching $474.14. The company had a trading volume of 308,992 shares, compared to its average volume of 584,417. The business has a fifty day simple moving average of $448.96 and a 200 day simple moving average of $363.80. The company has a market cap of $20.42 billion, a P/E ratio of 17.97, a P/E/G ratio of 4.96 and a beta of 0.77. United Therapeutics Corporation has a fifty-two week low of $266.98 and a fifty-two week high of $492.62.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 EPS for the quarter, beating analysts’ consensus estimates of $6.89 by $0.27. United Therapeutics had a return on equity of 18.83% and a net margin of 40.65%.The company had revenue of $799.50 million during the quarter, compared to analysts’ expectations of $812.87 million. During the same period in the prior year, the company earned $6.39 EPS. United Therapeutics’s revenue was up 6.8% compared to the same quarter last year. Research analysts forecast that United Therapeutics Corporation will post 24.48 EPS for the current year.

Institutional Investors Weigh In On United Therapeutics

A number of hedge funds have recently added to or reduced their stakes in UTHR. Darwin Global Management Ltd. bought a new position in shares of United Therapeutics during the 3rd quarter worth approximately $317,617,000. Norges Bank acquired a new position in shares of United Therapeutics during the 2nd quarter valued at $136,453,000. Invesco Ltd. boosted its stake in United Therapeutics by 90.2% during the second quarter. Invesco Ltd. now owns 884,703 shares of the biotechnology company’s stock worth $254,219,000 after acquiring an additional 419,588 shares in the last quarter. AQR Capital Management LLC boosted its stake in United Therapeutics by 40.1% during the second quarter. AQR Capital Management LLC now owns 1,273,161 shares of the biotechnology company’s stock worth $362,876,000 after acquiring an additional 364,713 shares in the last quarter. Finally, Nuveen LLC acquired a new stake in United Therapeutics in the first quarter worth $83,533,000. 94.08% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on UTHR shares. Oppenheimer lifted their price target on United Therapeutics from $510.00 to $575.00 and gave the company an “outperform” rating in a research note on Friday, September 5th. Weiss Ratings reiterated a “buy (b-)” rating on shares of United Therapeutics in a report on Monday. Jefferies Financial Group reissued a “buy” rating and set a $575.00 target price on shares of United Therapeutics in a report on Wednesday, November 19th. UBS Group raised their price target on shares of United Therapeutics from $580.00 to $600.00 and gave the company a “buy” rating in a research note on Thursday, November 6th. Finally, Royal Bank Of Canada lifted their price target on shares of United Therapeutics from $569.00 to $587.00 and gave the stock an “outperform” rating in a report on Thursday, October 30th. Eight equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $505.00.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.